Drug Type Universal CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Lymphoblastic Leukemia | Phase 1 | China | 10 Mar 2021 | |
| B-Cell Lymphoma | Phase 1 | China | 10 Mar 2021 | |
| CD19 Positive B-Cell Leukemia | Phase 1 | China | 10 Mar 2021 | |
| CD19 Positive Lymphoma | Phase 1 | China | 10 Mar 2021 | |
| CD19-positive B-cell acute lymphoblastic leukemia | Phase 1 | China | 10 Mar 2021 | |
| Chronic Lymphocytic Leukemia | Phase 1 | China | 10 Mar 2021 | |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | China | 10 Mar 2021 | |
| Recurrent Hematologic Malignancy | Phase 1 | China | 10 Mar 2021 |





